A groundbreaking study on a common form of lung cancer has found that more than half of the kinds of tumors that afflict patients could be targeted by drugs that either are in development or are already on the market. The study of squamous-cell lung cancer may herald a new era in cancer treatment in which cures are directed toward each cancer’s particular genetic makeup. The study was conducted in coordination with the National Institutes of Health’s Cancer Genome Atlas and drew on recent progress in DNA sequencing technologies.
Unlock a year of full access to The Daily Beast for $35.
Monthly
$1
First monththen $5.99/month
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $5.99 monthly. Cancel anytime
Annual
$35
First yearthen $59.99/year
Discounted annual rate - Save 47%
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $59.99 yearly. Cancel anytime
Best Value
Premium
$79
First yearthen $119.99/year
Discounted annual rate
Full access to the Daily Beast Substack ($60 value)*
Premium ad-free reading
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $119.99 yearly. Cancel anytime
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.
Subscription$0.00
Total$0.00
OR
Loading subscription options
Register below to read this article for free or subscribe to unlock unlimited access to The Daily Beast.
Monthly
$1
First monththen $5.99/month
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $5.99 monthly. Cancel anytime
Annual
$35
First yearthen $59.99/year
Discounted annual rate - Save 47%
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $59.99 yearly. Cancel anytime
Best Value
Premium
$79
First yearthen $119.99/year
Discounted annual rate
Full access to the Daily Beast Substack ($60 value)*
Premium ad-free reading
Unlimited access (web + app)
Exclusive ad-free newsletters
Commenting access
Daily crossword
Sneak peek of launches & events
Auto-renews at $119.99 yearly. Cancel anytime
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.